Antibody fragmentefgartigimod treatment of severe muscle weakness: Phase III trial welcomes fruit!
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Argenx recently released the latest data from the Phase III clinical (ADAPT study) of the antibody fragment efgartigimod for the treatment of severe muscle weakness (gMG), which showed that efgartigimod had reached its main endpoint"Patients have a quick and deep response to efgartigimod," said Wim Parys, Chief Medical Officer at ArgenxIn addition, the reaction lasted more than 8 or 12 weeks."The ADAPT trial recruited 167 gMG patients with a total mg-ADL score of 5 or moreParticipants were able to participate in the study regardless of their acetylcholine receptor antibody statusThey also received at least one gMG treatment, including acetylcholinesterase inhibitors, corticosteroids, or nonsteroidal immunosuppressive drugs, before being randomly groupedThe results showed that 63.1% of Patients with AChR-Ab plus had a reaction to efgartigimod in terms of severe muscle weakness (QMG) scores, compared with only 14.1% of patients in the placebo groupgMG is a chronic neuromuscular disease that causes varying degrees of muscle weaknessMost commonly affect stoliamuch musclesIt can cause symptoms such as resuscitation, drooping eyelids, difficulty speaking and difficulty walkingSevere muscle weakness can occur suddenly
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
